Design / Somatic gene editing
Editing with a purpose
Gene editing has reached approved treatment in specific settings. That is a precise milestone, not universal editability.
What the evidence shows
CASGEVY is a CRISPR-edited cellular therapy with FDA-approved indications for specific blood disorders.
What we can reasonably infer
The approved pathway provides experience that may inform other carefully evaluated somatic therapies.
What remains a possibility
Broad, safe enhancement of healthy people is not established by these approvals.
THE BOUNDARY
Where the claim stops
An approval is specific to a product, indication, and treatment process. It does not validate DIY editing or heritable enhancement.
THE NEXT USEFUL SIGNAL
What to watch for
Long-term follow-up, delivery improvements, and indication-specific clinical evidence.
The horizon is an editorial scenario for this brief’s central possibility. It does not predict a treatment date or an investment return.